Apollo Endosurgery, Inc. APEN
We take great care to ensure that the data presented and summarized in this overview for Apollo Endosurgery, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding APEN
View allLatest Institutional Activity in APEN
Top Purchases
Top Sells
About APEN
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Insider Transactions at APEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 04
2023
|
R Kent Mc Gaughy Jr |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,183,603
-100.0%
|
-
|
Apr 04
2023
|
Cpmg Inc |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
6,183,603
-100.0%
|
-
|
Apr 04
2023
|
Jeffrey G. Black Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
335,330
-100.0%
|
-
|
Apr 04
2023
|
Mike Gutteridge VP, Int'l Sales and Marketing |
SELL
Sale (or disposition) back to the issuer
|
Direct |
86,647
-100.0%
|
-
|
Apr 04
2023
|
Christopher J. Gostout Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
90,267
-100.0%
|
-
|
Apr 04
2023
|
John J Molesphini EVP, Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
92,626
-100.0%
|
-
|
Apr 04
2023
|
William D. Mc Clellan Jr. Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
2,000
-100.0%
|
-
|
Apr 04
2023
|
William D. Mc Clellan Jr. Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,249
-100.0%
|
-
|
Apr 04
2023
|
Chas Mc Khann President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
689,880
-100.0%
|
-
|
Apr 04
2023
|
Sharon O'Keefe Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
35,604
-100.0%
|
-
|
Apr 04
2023
|
Jeannette Bankes Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,641
-100.0%
|
-
|
Apr 04
2023
|
John R Barr Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
44,082
-100.0%
|
-
|
Apr 04
2023
|
David Pacitti Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,112
-100.0%
|
-
|
Apr 04
2023
|
Julie Ann Shimer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
36,021
-100.0%
|
-
|
Dec 28
2022
|
Cpmg Inc |
BUY
Conversion of derivative security
|
Indirect |
2,198,655
+25.73%
|
$6,595,965
$3.25 P/Share
|
Dec 28
2022
|
R Kent Mc Gaughy Jr |
BUY
Conversion of derivative security
|
Indirect |
2,198,655
+25.73%
|
$6,595,965
$3.25 P/Share
|
Nov 04
2022
|
Jeffrey G. Black Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,060
-4.33%
|
$90,360
$6.46 P/Share
|
Aug 05
2022
|
Jeffrey G. Black Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,190
-1.75%
|
$37,140
$6.46 P/Share
|
Aug 05
2022
|
Sharon O'Keefe Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,604
+50.0%
|
-
|
Jun 14
2022
|
John R Barr Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,224
+24.4%
|
-
|